Lv71
4910 积分 2021-08-21 加入
Nonoperative Management of Mismatch Repair–Deficient Tumors
1个月前
已完结
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial
3个月前
已完结
Integrating CTLA-4/PD-1 blockade into cervical cancer management: Results of COMPASSION-16
3个月前
已完结
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update
4个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
5个月前
已完结
Decoding the interplay between genetic and non-genetic drivers of metastasis
10个月前
已完结
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
11个月前
已完结
Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma – a Role in Patients with Para-aortic Lymph Node Involvement? A 10-year Institutional Experience
11个月前
已完结
Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines
11个月前
已完结
Breast cancer exploits neural signaling pathways for bone-to-meninges metastasis
1年前
已完结
皖公网安备34019202002308
